Abstract:Krabbe disease (KD) is an autosomal recessive lysosomal storage disorder caused by loss–of–function mutations in the GALC gene, which encodes for the enzyme galactosylceramidase (GALC). GALC is crucial for myelin metabolism. Functional deficiency of GALC leads to toxic accumulation of psychosine, dysfunction and death of oligodendrocytes, and eventual brain demyelination. To date, 46 clinically–relevant, pathogenic GALC missense mutations (MMs) have been identified in KD patients. These MMs are present in ~70% of KD cases reported over 8 published studies between 1996 – 2019. However, the mechanisms by which these MMs lead to GALC functional deficiency and their correlations with clinical phenotype remain poorly understood. To address this, we generated a GALC–knockout human oligodendrocytic cell line (MO3.13/ GALC–KO) using CRISPR–Cas9 method to assess GALC function and GALC secretion. We evaluated 5 polymorphic and 31 clinically–relevant MM variants (MMVs) using transient expression assays. Our results showed that 26 MMVs, including 10 co–variants with p.I562T, reduced GALC activity by 92% – 100% compared to wildtype GALC (WT–GALC). MMVs from infantile-onset KD patients produced < 2% of WT activity, whereas those associated with juvenile– and adult–onset cases retained up to 7% of WT activity. Residual GALC activity was correlated with mature, lysosomal GALC protein levels (Pearson r = 0.93, P<0.0001). Many low–activity MMVs did not correspondingly impair GALC secretion. Twenty–one of the 26 low–activity MMVs showed a 21% – 100% reduction in sec–GALC levels, indicating varying degrees of GALC mis–trafficking among these variants. Importantly, GALC activity among MMVs strongly correlates with clinical disease severity, based on the age of symptom onset in patients with either homozygous MM (Pearson r = 0.98, P<0.0001, n = 7) or compound heterozygous (Pearson r = 0.94, P<0.0001, n = 12) MM–null mutation genotypes. Thus, our data suggests that GALC activity could serve as a prognostic disease indicator under specific experimental conditions. We further investigated the impact of pathogenic MMVs on psychosine accumulation, a key biomarker for KD. Psychosine levels were 21–fold higher in mock control cells compared to WT–GALC transfected cells (mock = 0.349 pmol/mg, WT–GALC = 0.016 pmol/mg), but negatively correlated with GALC activity among pathogenic MMVs (Pearson r = –0.63, P < 0.01, n = 15). Although psychosine levels were higher in most MMVs associated with infantile–onset KD, no significant correlations with clinical onset were detected. Overall, our study provides a comprehensive quantitative analysis of the functional deficits and mis–trafficking associated with clinically–relevant GALC MMVs, enhancing our understanding of the molecular genetics and genotype–phenotype correlations of the GALC gene in Krabbe disease.

Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease

CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease

RP-CARS reveals molecular spatial order anomalies in myelin of an animal model of Krabbe disease

Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease

The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease

From pathological mechanisms in Krabbe disease to cutting‐edge therapy: A comprehensive review

Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease

Chronic Rapamycin administration via drinking water mitigates the pathological phenotype in a Krabbe disease mouse model through autophagy activation

Late‐onset Krabbe disease presenting as spastic paraplegia – implications of GCase and CTSB/D

Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?

Novel GALC Mutations Cause Adult-Onset Krabbe Disease With Myelopathy in Two Chinese Families: Case Reports and Literature Review

Efficacy and Safety of a Krabbe Disease Gene Therapy

Natural history of Krabbe disease – a nationwide study in Germany using clinical and MRI data

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials

Large-scale study of clinical and biochemical characteristics of Chinese patients diagnosed with Krabbe disease.

Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report

Krabbe disease: New hope for an old disease

Expression study of Krabbe Disease GALC missense variants — Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels

Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target

Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor

Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior